ReviewFrontiers in endocrinology2026
Continuous glucose monitoring after discontinuation of incretin-based obesity pharmacotherapy: indirect evidence and a research framework for metabolic stability and weight maintenance.
Review in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Discontinuation of incretin-based pharmacotherapy is frequent and is associated with weight regain and metabolic relapse, including deterioration in cardiometabolic risk factors. New strategies are needed to preserve metabolic stability and body weight after treatment withdrawal. Whether continuous glucose monitoring (CGM) can facilitate early detection of metabolic relapse or support long-term weight maintenance after discontinuation remains unknown. This narrative review examines the indirect evidence supporting CGM use after discontinuation of incretin-based obesity pharmacotherapy, focusing primarily on adults with obesity without established diabetes, including those with normoglycemia or prediabetes. CGM can characterize postprandial glucose responses and glycemic variability under free-living conditions while also offering real-time behavioral feedback. However, no prospective studies have established whether CGM-derived metrics precede or predict weight regain, nor whether CGM-guided interventions improve long-term weight-maintenance outcomes in this setting. Moreover, validated CGM thresholds for identifying metabolic relapse in individuals without diabetes have yet to be defined. We outline a hypothesis-generating three-phase monitoring framework for the prospective evaluation of CGM alongside body weight, appetite, dietary intake, and physical activity during the post-discontinuation transition period. If validated, unfavorable CGM trends could support earlier individualized behavioral or pharmacological intervention, before clinically meaningful weight regain or metabolic relapse occurs. Potential benefits must be balanced against costs, skin reactions, anxiety, and unnecessary dietary restrictions arising from overinterpreting unvalidated signals. CGM-guided post-pharmacotherapy care, therefore, remains investigational and requires prospective validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.